NEUROPROTECTIVE EFFECTS OF CROMAKALIM ON CEREBRAL ISCHEMIA-REPERFUSION (IR) INJURY AND ALUMINIUM INDUCED TOXICITY IN RAT BRAIN

*1PITHADIA ANAND BHARAT KUMAR, 2SHITAL PANCHAL

*1Department of Pharmacology, Parul Institute of Pharmacy, Vadodara, 2Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India.

Email: abpithadia@hotmail.com

Received: 29 Apr 2014 Revised and Accepted: 28 May 2014

ABSTRACT

Objective: Preclinical studies have demonstrated that potassium channel openers show a neuroprotective effect on cerebral ischemia-reperfusion (IR) injury in rats. However, their mechanism of action and effects in brain stroke related disorders such as Alzheimer’s disease (AD) remain poorly understood. Hence present study was done to investigate the prophylactic use of the adenosine triphosphate-sensitive (ATP) potassium channel opener, cromakalim, on neurological function in rats with cerebral IR injury and its related disorders AD.

Methods: Male Wistar rats were randomly assigned to 6 groups (n = 36): Normal control, aluminium chloride(AlCl3) control, AlCl3 Sham operated, ischemia reperfusion (IR) control, AlCl3-IR control and AlCl3-IR with cromakalim treatment. Cromakalim10 mg/kg intra peritonially (i.p.) was administered daily for 42 days in middle cerebral artery occluded rats treated with AlCl3. At 24 hours post-surgery, neurological score, brain hemisphere weight difference, brain acetylcholinesterase level, lipid peroxidation, Na+/K+ ATPase pump activity and super oxide dismutase level were measured.

Results: Following cerebral ischemia-reperfusion injury along with aluminium chloride, neurological score, brain hemisphere weight difference, brain acetylcholinesterase level, malondialdehyde levels were significantly high while Na+/K+ ATPase pump activity and super oxide dismutase(SOD) levels were significantly lower in diseased animals (P < 0.05). Treatment with cromakalim significantly reduced neurological score, brain hemisphere weight difference, brain acetyl cholinesterase level, malondialdehyde levels while raised Na+/K+ ATPase pump activity and super oxide dismutase levels (P < 0.05).

Conclusion: Hence results of our study demonstrated the neuroprotective potential of cromakalim in cerebral IR injury and its related disorders AD.

Keywords: Cerebral ischemia-reperfusion, Cromakalim, Aluminium, Alzheimer’s disease, Oxidative stress, Neuroprotection.

INTRODUCTION

Stroke is an interruption in the supply of blood to a particular part of the brain. There are two main causes of stroke. Either a blood vessel within the brain becomes clogged or blocked (ischemic stroke-IS, about 83% of strokes) or it ruptures, causing blood to leak into the brain (haemorrhagic stroke) [1]. It is well reported that stroke more than doubles the risk of developing dementia and AD and around one in three people who have a stroke develop dementia [2]. Clinical diagnosis of ADs associated with considerably increased risk of stroke development and patients with AD have a higher risk of IS (ischemic stroke) and ICH (intra cerebral hemorrhage) [3]. Further epidemiological studies show that risk factors for AD have a vascular basis and practically all drugs reported to slow the development of AD, improve or increase cerebral perfusion. Evidence that cerebral hyperperfusion appears to precede the cognitive, and degenerative pathology that is present in AD. Current treatment of brain stroke includes tissue plasminogen activators, antiplatelet agents and anticoagulants for their antithrombotic effects. Reports showed that free radical scavengers, minocycline and growth factors have shown neuroprotective effects in the treatment of stroke, while antihypertensive drugs, lipid-lowering drugs and oral antidiabetic drugs have shown beneficial effects for the prevention of stroke [4]. However, these agents are associated with number of side effects. Therefore, there is a need to identify new targets and molecules in central nervous system (CNS) that provide neuroprotection in stroke related disorders. One of them is the ion channel for Na+, K+, Ca2+ and Cl−. They play a crucial role in controlling a very wide spectrum of physiological processes. Their dysfunction can produce various CNS diseases. Hence new generation of therapeutic agents are expected to result from targeting this ion channels.

Further, it is well established that K+ channels are widely expressed in CNS and are gaining attention for their beneficial roles in neuroprotection. Dysfunction of potassium channel leads to change in neuronal physiological processes and results in pathophysiology of various diseases including stroke, epilepsy, pain and cognition [5]. Hence K+ channels are recognized as potential therapeutic targets in the treatment of CNS disorders. Adenosine triphosphate-sensitive potassium channel (K_ATP) openers such as cromakalim provide neuroprotection against cerebral ischemia-reperfusion injury by reducing inflammation and free radical mediated oxidative stress. Neuroprotective effects of cromakalim have been already established on cerebral ischemia-reperfusion injury in rats [6]. Hence present study hypothesized that K_ATP openers could reduce stroke as well as stroke related disorders such as AD by providing neuroprotection. Rat model of cerebral ischemia-reperfusion was established through middle cerebral artery occlusion using the suture method [6] and this was preceded by AlCl3 to induce cholinergic nerve damage as that of Alzheimer’s disease in same animals [7]. The effects of prophylactic use of the K+ channel opener, cromakalim, on neurological function, brain acetylcholinestares level and lipid peroxidation parameters were determined to explore the mechanisms of action of cromakalim for neuroprotection.

MATERIALS AND METHOD

Drugs and Chemicals

Cromakalim was gifted from Dr. Anjali Tarai, Assistant Professor, Department of Pharmacology, VSS Medical College, Cuttack, Orissa, India. Other chemicals used in experiment were of laboratory grade. Cromakalim solution was prepared freshly by dissolving it in sterile distilled water and injected i.p. with dose 10 mg/kg, AlCl3 solution was made freshly in sterile distilled water at the beginning of each experiment and given orally at dose of 100 mg/kg.

Animals

Healthy adult male Wistar rats (250 gm) aged 8 months were selected for the study. Animals were maintained at 18±2°C and kept in well ventilated animal house in polypropylene cages with free
access to food and water. All studies was done with prior permission from IAEC of Parul Institute of Pharmacy (921/PO/AC/05/ CPCSEA) and Study was approved as Protocol No PIPH 21/13. Animals were divided into six groups. Group 1 served as normal control (n=6) and received distilled water. Group 2 serve as ACl control and received ACl at dose 100 mg/kg per oral for a period of 42 days (6 weeks). Group 3 served as ACl Sham operated (n=12) and treated with ACl at dose 100 mg/kg per oral for a period of 42 days (6 weeks). Sham operation was performed on 41st day. Group 4 served as ischemia-reperfusion (IR) control (n=6) and received distilled water for 42 days. Cerebral ischemia—reperfusion was performed on 41st day from initiation of experiment. Group 5 served as ACl-IR control (n=6) and animals were treated with ACl, at dose 100 mg/kg per oral for a period of 42 days (6 weeks). Cerebral IR was performed on 41st day from initiation of experiment. Group 6 treated with ACl and cranolakim (n=6) along with IR injury. These animals were treated with ACl at dose 100 mg/kg per oral and cranolakim at dose 10 mg/kg (ip) for a period of 42 days (6 weeks). Cerebral IR was performed on 41st day from initiation of experiment. Cerebral IR was induced as per MCAO (transient middle cerebral artery occlusion) method [6]. Rats were anesthetized with an I.P. injection of 100 mg/kg ketamine. A 2.5 cm incision was made in the middle of the neck line, separating the left carotid artery, the superior thyroid artery, and the occipital artery, as well as the internal and external carotid communicating arteries. The occipital artery branches of external carotid artery (ECA) were isolated and tied with a cotton thread. Cotton thread was tied loosely around the ECA stump near the bifurcation. Then internal carotid artery (ICA) and common carotid artery (CCA) were temporarily occluded by fine vessel clip. Through a small incision to the ECA stump, blunt Poly-L-lysine coated 4-0 monofilament was inserted from the left external carotid artery into the left internal carotid artery to a depth of 18.0 mm, vessel clip from ICA removed. After a variable length of suture had been inserted into ECA stump, resistance was felt and slight curving of suture was observed, indicating that suture had passed middle cerebral artery (MCA) origin and reached to proximal segment of anterior cerebral artery (ACA-it has small diameter). Hence suture had blocked all sources of blood from ICA, ACA and posterior cerebral artery. Finally vessel clip from CCA was removed to restore blood flow. The midline incision was closed, leaving suture protruding so it could be withdrawn to allow reperfusion. The thread was maintained for 2 hours and subsequently removed to restore blood flow to the common carotid and internal carotid arteries. Here 18 mm of suture was pulled back until resistance was felt, indicating that tip cleared the ACA-ICA lumen and was in ECA stump, then trimmed. The animals were transfer to a fresh cage with free access to food and water.

**Tissue homogenate preparation**

At the end of the study, animals were sacrificed, brain were dissected out and washed with 0.9% NaCl and stored at −40 °C for further processing. Brain was homogenized in 10% (w/v) ice-cold 0.1 M phosphate buffer solution (pH 7.4). The lipid peroxidation (LPO) was estimated with a ratio of crude homogenate and the rest homogenate was centrifuged at 12,000 rpm for 20 min to obtain the supernatant which was used for enzymatic estimations [7].

**Tissue total protein level**

It was measured using bovine serum albumin as standard, alkaline copper reagent Solution A (2% sodium carbonate in 0.1 NaOH solution in distilled water) and solution B (0.5% copper sulphate in 1% sodium potassium tartarate). 50.0 ml of solution A was mixed with 1.0 ml of solution B just before use. Folin’s phenol reagent was obtained commercially. One volume of Folin’s phenol reagent was diluted with 1 volume of distilled water just before use. 20.00 mg standard bovine serum albumin (BSA) was dissolved in 100 ml distilled water. Few drops of NaOH were added to aid complete dissolution of BSA and to avoid frothing. 10 ml of the stock solution was diluted to 100ml to get a working standard (200 µg/ml). Procedure 0.1 ml crude homogenate was used for protein extraction. The protein was extracted by mixing with 5% cold trichloroacetic acid and centrifuged. The pellet was solubilized with 0.5 N sodium hydroxide and stored over-night at room temperature. After neutralization with 0.5 N HCL, 0.2 ml of diluted solution and different concentrations of standard were taken. The volume was made up to 1.0 ml with distilled water. Blank contained 1.0 ml distilled water.

To all the tubes 5.0 ml alkaline copper reagent was added and left at room temperature for 10 Min. 0.5 ml of folin’s phenol reagent was added and the blue color developed was read after 20 minutes at 660nm against reagent blank in a spectrophotometer. Protein concentration is expressed as mg/gm of wet brain tissue [8].

**Brain acetylcholinesterase level**

It is a marker of the loss of cholinergic neurons in the forebrain. The assay mixture contained 0.05 ml of supernatant, 3 ml of sodium phosphate buffer (pH 8), 0.1 ml of acetylthiocholine iodide and 0.1 ml of DTNB (Ellman reagent). The change in absorbance was measured for 2 min at 30 s intervals at 412 nm. Results were expressed as micromoles of acetylthiocholine iodide hydrolyzed/min/mg of protein [9].

**Malondialdehyde (MDA)**

It is a marker of lipid peroxidation. 1 ml of homogenate was incubated at 37 °C for 10 min. 1 ml of 10% trichloroacetic acid (TCA) chilled (w/v) was added to it and centrifuged at 2500 rpm for 15 min at room temperature. 1 ml of 0.67% TBA was added to 1 ml of supernatant and kept in a boiling water bath for 10–15 min. The tubes were cooled under tap water. After cooling 1 ml of distilled water was added to it and absorbance was taken at 530 nm. The results were expressed as micromoles/mg of protein [10].

**Superoxide dismutase (SOD)**

An aliquot of 0.25 ml ice-cold chloroform was added to 0.1 ml of supernatant followed by addition of 0.15 ml ice-cold ethanol. The mixture was centrifuged at 3000 rpm for 10 min at 4 °C. 0.2 ml the supernatant was taken and 1.3 ml buffer, 0.5 ml EDTA, and 0.8 ml water were added. Reaction was started by adding 0.2 ml epinephrine. Change in absorbance for optical density/minute at 405 nm was read for 3 min. The results were expressed in terms of units/mg protein. One unit of enzyme activity is defined as the concentration required for the inhibition of the chromogen production by 50% in one minute under the defined assay conditions [11].

**Na+/ K+ ATPase pump activity**

The incubation mixture containing 0.1 ml of each i.e. tris HCL, 50 mM magnesium sulphate, 650 mM NaCl, 50 mM KCl, 1 mM EDTA, 40 mM ATP and brain homogenate. Mixture was incubated at 36 °C for 15 minutes. The reaction was arrested by addition of 1 ml 10% TCA and resultant mixture was centrifuged for 5 min 0.5 ml supernatant was taken, 2.5 ml 0.5 ml of 25 % ammonium molybdate and 0.25 ml ANSA (1-amino 2-naphthol 4-sulphonic acid) was added. The mixture was incubated at 67 °C for 10 minutes. The intensity of blue color developed against blank at 620 nm. Results were expressed as nmoles of inorganic phosphorus liberated/min/mg protein. Standard calibration curve was prepared using potassium dihydrogen phosphate (2-15 µg/ml) [12].

**Brain hemisphere weight difference**

The MCA occluded animals were anaesthetised with high dose of pentobarbitone. The skull was opened and whole brain was removed immediately, rinsed with ice cold distilled water followed by 20% sucrose and dried using blotting paper. The ipsilateral and contralateral parts of brain are isolated and weighed on digital balance. Weight difference was calculated between ipsilateral and contralateral brain region of each animal [13].

**Neurobehavioral function scores**

Neurological score was observed after 24 hours of IR [14]. This score was observed for group 4, 5 and 6.

**Score 0**: No apparent deficit

**Score 1**: Contralateral forelimb flexion when suspended by tail

**Score 2**: Decreased grip of the contralateral forelimb while tail pulled
Score 3: Spontaneous movement in all direction or contralateral circling only if pulled by tail.
Score 4: Spontaneous contralateral circling
Score 5: Death after recovery from anaesthesia.

Statistical methods
Data are expressed as mean values ± S.E.M and analyzed using one-way ANOVA followed by Post-hoc Tukey’s tests to identify two group differences using Prism software at 5% significance level.

RESULTS
Brain acetylcholinesterase levels
Administration aluminium chloride for 42 days significantly raised cholinesterase level in AlCl₃ treated control animals (73.07 ± 2.05) and AlCl₃ Sham operated animals (64.10 ± 0.84) when compared with normal animals(19.49 ± 0.55).Ischemia reperfusion(IR) injury along with AlCl₃ also significantly raised (96.86 ± 1.07) cholinesterase level when compared with IR control (24.01 ± 0.54).

Treatment of cromakalim significantly reduced brain acetylcholinesterase level (26.33 ± 0.37) when compared with AlCl₃ IR control animals (table 1).

Brain malondialdehyde(MDA) levels(n=6)
Administration aluminium chloride for 42 days significantly raised MDA level in AlCl₃ also significantly raised (96.86 ± 1.07) cholinesterase level when compared with IR control (24.01 ± 0.54).

Treatment of cromakalim significantly reduced brain MDA level (39.90 ± 0.45) when compared with AlCl₃ IR control animals (table 2).

Brain SOD levels (n=6)
Administration aluminium chloride for 42 days significantly reduced SOD level in AlCl₃ treated control animals (84.54 ± 0.83) and AlCl₃ Sham operated animals (73.59 ± 0.85) when compared with normal animals(259.76 ± 0.80).Ischemia reperfusion(IR) injury along with AlCl₃ also significantly reduced (163.3 ± 1.93) SOD level when compared with IR control (22.78 ± 0.48).

Treatment of cromakalim significantly raised brain SOD level (143.49 ± 0.68) when compared with AlCl₃ IR control animals (table 3).

Na⁺/K⁺-ATPase activity (nm/mg protein) (n=6)
Administration aluminium chloride for 42 days significantly reduced Na⁺/K⁺-ATPase activity level in AlCl₃ treated control animals (37.24 ± 0.60) and AlCl₃ Sham operated animals (22.12 ± 0.39) when compared with normal animals(61.27 ± 0.47).

Ischemia reperfusion(IR) injury along with AlCl₃ also significantly reduced (22.95 ± 0.43) Na⁺/K⁺-ATPase activity when compared with IR control (10.12 ± 0.38). Treatment of cromakalim significantly raised brain Na⁺/K⁺-ATPase activity (47.96 ± 0.29) when compared with AlCl₃ IR control animals (table 4).

Table 1: Brain cholinesterase activity μ mol of acetyl thiocholine iodide hydrolyzed/ minute (min)/milligram (mg) of protein(n=6)

<table>
<thead>
<tr>
<th>Groups</th>
<th>Brain cholinesterase levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Control</td>
<td>19.49 ± 0.55</td>
</tr>
<tr>
<td>AlCl₃ control</td>
<td>73.07 ± 2.05*</td>
</tr>
<tr>
<td>AlCl₃ Sham operated</td>
<td>64.10 ± 0.84*</td>
</tr>
<tr>
<td>IR control</td>
<td>24.01 ± 0.54*</td>
</tr>
<tr>
<td>AlCl₃ IR control</td>
<td>96.86 ± 1.07**</td>
</tr>
<tr>
<td>AlCl₃ cromakalim IR</td>
<td>26.33 ± 0.37***</td>
</tr>
</tbody>
</table>

* Significant different than normal control (p<0.05), **Significant different than IR control group (p<0.05), *** Significant different than AlCl₃ IR control (p<0.05)

Table 2: Brain malondialdehyde (MDA) levels

<table>
<thead>
<tr>
<th>Groups</th>
<th>MDA(μmoles/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Control</td>
<td>14.20 ± 1.86</td>
</tr>
<tr>
<td>AlCl₃ control</td>
<td>128.92 ± 3.46*</td>
</tr>
<tr>
<td>AlCl₃ Sham operated</td>
<td>78.72 ± 1.46*</td>
</tr>
<tr>
<td>IR control</td>
<td>77.23 ± 1.94*</td>
</tr>
<tr>
<td>AlCl₃ IR control</td>
<td>121.143 ± 1.67**</td>
</tr>
<tr>
<td>AlCl₃ cromakalim IR</td>
<td>39.90 ± 0.45***</td>
</tr>
</tbody>
</table>

* Significant different than normal control (p<0.05), **Significant different than IR control group (p<0.05)

Table 3: Brain SOD levels

<table>
<thead>
<tr>
<th>Groups</th>
<th>SOD(munits/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Control</td>
<td>259.76 ± 0.80</td>
</tr>
<tr>
<td>AlCl₃ control</td>
<td>84.54 ± 0.83*</td>
</tr>
<tr>
<td>AlCl₃ Sham operated</td>
<td>73.59 ± 0.85*</td>
</tr>
<tr>
<td>IR control</td>
<td>22.78 ± 0.48*</td>
</tr>
<tr>
<td>AlCl₃ IR control</td>
<td>16.33 ± 1.93**</td>
</tr>
<tr>
<td>AlCl₃ cromakalim IR</td>
<td>143.49 ± 0.68***</td>
</tr>
</tbody>
</table>

* Significant different than normal control (p<0.05), ** Significant different than IR control group (p<0.05), *** Significant different than AlCl₃ IR control (p<0.05)
Hemisphere weight difference (n=6)

Administration aluminium chloride for 42 days significantly raised brain hemisphere weight difference in AlCl₃ treated control animals (0.016 ± 0.002) and AlCl₃ Sham operated animals (0.022 ± 0.003) when compared with normal animals(0.0062 ± 0.0003).Ischemia reperfusion(IR) injury along with AlCl₃ also significantly increased (0.077 ± 0.003) brain hemisphere weight difference when compared with normal control. However, this is nonsignificant when compared with IR control (0.071 ± 0.005).

Treatment of cromakalim significantly reduced brain hemisphere weight difference (0.039 ± 0.0038) when compared with AlCl₃ IR control animals (table 5).

Neurological score (n=6)

Treatment of cromakalim significantly reduced brain neurological damage (1.2 ± 0.12) when compared with animals treated with IR alone with AlCl₃ (4.22 ± 0.15) as well as IR control animals (3.20 ± 0.16) (table 5).

Table 4: Na⁺/K⁺ ATPase activity (nm/mg protein)

<table>
<thead>
<tr>
<th>Groups</th>
<th>(nm/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Control</td>
<td>61.27 ± 0.47</td>
</tr>
<tr>
<td>AlCl₃ control</td>
<td>37.24 ± 0.60*</td>
</tr>
<tr>
<td>AlCl₃ Sham operated</td>
<td>22.12 ± 0.39*</td>
</tr>
<tr>
<td>IR control</td>
<td>10.12 ± 0.38*</td>
</tr>
<tr>
<td>AlCl₃ IR control</td>
<td>22.95 ± 0.43***</td>
</tr>
<tr>
<td>AlCl₃ cromakalim IR</td>
<td>47.96 ± 0.29***</td>
</tr>
</tbody>
</table>

* Significant different than normal control (p<0.05), ** Significant different than IR control group (p<0.05), *** Significant different than AlCl₃ IR control (p<0.05)

Table 5: Hemisphere weight difference

<table>
<thead>
<tr>
<th>Groups</th>
<th>Gm/100 gm body weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Control</td>
<td>0.0062 ± 0.0003</td>
</tr>
<tr>
<td>AlCl₃ control</td>
<td>0.016 ± 0.0002*</td>
</tr>
<tr>
<td>AlCl₃ Sham operated</td>
<td>0.022 ± 0.003*</td>
</tr>
<tr>
<td>IR control</td>
<td>0.071 ± 0.003*</td>
</tr>
<tr>
<td>AlCl₃ IR control</td>
<td>0.077 ± 0.003 (NS)</td>
</tr>
<tr>
<td>AlCl₃ cromakalim IR</td>
<td>0.039 ± 0.0038**</td>
</tr>
</tbody>
</table>

* Significant different than normal control (p<0.05), *** Significant different than AlCl₃ IR control (p<0.05), NS is Non-significant when compared with IR control

Table 6: Neurological score

<table>
<thead>
<tr>
<th>Groups</th>
<th>Gm/100 gm body weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>IR control</td>
<td>3.20 ± 0.16</td>
</tr>
<tr>
<td>AlCl₃ IR control</td>
<td>4.22 ± 0.15</td>
</tr>
<tr>
<td>AlCl₃ cromakalim IR</td>
<td>1.2 ± 0.12*</td>
</tr>
</tbody>
</table>

* Significant different than AlCl₃ IR control (p<0.05)

DISCUSSION

In present study we have made an attempt to evaluate efficacy of KATP channel opener cromakalim against ischemic-reperfusion type of brain stroke model in AlCl₃ treated rats. The symptoms produced by IR along with AlCl₃ resembles to a great extent with that observed in clinical status. Research studies have demonstrated that three months after stroke model in AlCl₃ treated rats. It has been suggested that aluminium is a contributing factor in the pathogenesis of Alzheimer’s disease. Hence to induce neurotoxicity as observed in AD, aluminium chloride was used [7] and cerebral ischemia –reperfusion was performed on 41th day from initiation of experiment in same animals. Our objective of study was to investigate neuroprotective effect of cromakalim (potassium channel opener) on cerebral ischemic stroke in aluminium chloride induced neuronal toxicity in rats. Cromakalim is ATP sensitive potassium channel opener and it improves neurological function and reduced cerebral infarction volume in rats [6].

Studies have shown that oxidative stress is increased during acute cerebral ischemia and plays a key role in ischemic nerve injury. It is well reported that during IR injury along with aluminium anti-oxidant mechanisms are compromised and hence it raise lipid peroxidation (malondialdehyde-MDA level) and reduced super oxide dismutase (SOD) levels in diseased control animal [15]. In present study, cromakalim significantly lowers value of MDA and increased level of SOD in IR-aluminium treated rats. Thus prevent lipid peroxidation and oxidative stress. This suggest anti-oxidant role of cromakalim to produce neuroprotection. Aluminium crosses the blood brain barrier and induces inflammatory responses and inhibits long-term potentiation, and causes synaptic structural abnormalities, thereby resulting in profound memory loss [16]. Aluminium raises brain acetylcholinesterase level, cause neurodegeneration and neuroinflammation. It itself results into oxidative damage to brain and cognitive dysfunction.

Aluminium has a biphasic effect on acetylcholinesterase activity, with an initial increase in the activity of this enzyme during the first 2 weeks of exposure followed by a marked decrease. These results into slow accumulation of aluminium in the brain [17, 18, 19] and this would contribute to the increase in acetylcholinesterase activity as observed in the aluminium chloride treated rats. Further, it was well established that more level of same enzyme is responsible for Alzheimer’s disease to damage cholinergic neurones. Chronic administration of cromakalim was found to reduce brain acetylcholinesterase level and also reduced oxidative damage induced by ischemia –reperfusion injury along with chronic aluminium administration. Hence from data of our study, cromakalim...
treatment prevents cholinotoxic effect of aluminium on neurones in IR-aluminium treated rats. This is further supported by significant lower value of neurological damage score in cromakalim treated animals when compared with IR control animals and AlCl₃-IR animals. Cromakalim significantly raised Na⁺/K⁺ ATPase pump activity and reduced brain hemisphere weight difference. As it is well understood that neuronal cell damage by ischemic injury and by chronic aluminium administration interrupt activity of Na⁺/K⁺ ATPase pumps which maintain cellular water level. Due to inhibition of this pump, extracellular potassium accumulates and at the same time that sodium and water are sequestered intracellular and leading to cell swelling, its lysis and raised brain hemisphere weight difference [20]. Hence our report show role of cromakalim in prevention of this cell injury.

Hence our results show that cromakalim significantly improves neurological functions at 24 hours post-surgery, and provide neuroprotection as observed by reduced acetylcholinesterase level, malondialdehyde level, the neurological score, brain hemisphere neuroprotection as observed by reduced acetylcholinesterase level, neurological functions at 24 hours post-surgery, and provide difference [20]. Hence our report show role of cromakalim in prevention of this cell injury.

CONCLUSION
In present study, results suggests that pre-treatment with cromakalim (10 mg/kg i.p.) produce neuroprotective effect in AlCl₃-IR animals as indicted by reduction in, neurological deficit, malondialdehyde, cholinesterase enzyme and raised anti-oxidant enzyme defence. This protective effect might be due to free radical scavenging effect, enhancing anti-oxidant enzyme and reducing cholinesterase activity.

ACKNOWLEDGEMENTS
The authors are thankful to Dr. Anjali Tarai, Assistant Professor, Department of Pharmacology, VSS Medical College, Cuttack, Orissa, India for providing gift sample of cromakalim and Dr. Rajesh KS, Principal, Parul Institute of Pharmacy for providing necessary infrastructure for experimental work at Parul Institute.

CONFLICT OF INTEREST
We declare that we have no conflict of interest.

REFERENCES


